t-cell Europe GmbH, a near Berlin, Germany-based developer of and novel T-cell-based therapies based on its IP-protected platform technology, has completed its €1.45m first financing round.
Backers include High-Tech Gruenderfonds, Constantin Bastian Leander Venture Capital GmbH, and the Brandenburg state development bank (ILB).
The company intends to use the financing to continue the development activities as well as the validation efforts of its platform technology according to pharmaceutical standards so that it may subsequently proceed to clinical studies.
Founded in 2010 as a spin-off of the Berlin-Brandenburg Center for Regenerative Therapies, the Kleinmachnow-based start-up is currentlybdeveloping the Treg-cell product for use in conjunction with kidney transplants.
t-cell Europe is led Dr. Claudia Ulbrich, CEO.